TY - JOUR
T1 - Targeting ability of self-assembled nanomedicines in rat acute limb ischemia model is affected by size
AU - Suhara, Masamitsu
AU - Miura, Yutaka
AU - Cabral, Horacio
AU - Akagi, Daisuke
AU - Anraku, Yasutaka
AU - Kishimura, Akihiro
AU - Sano, Masaya
AU - Miyazaki, Takuya
AU - Nakamura, Noriko
AU - Nishiyama, Ayako
AU - Kataoka, Kazunori
AU - Koyama, Hiroyuki
AU - Hoshina, Katsuyuki
N1 - Funding Information:
This research was financially supported by Grants-in-Aid for Young Scientists (A; No. 24689051) Grants-in-Aid for Scientific Research (B; No. 16H05422) to Y.M., Grants-in-Aid for Scientific Research (C; No. 26462100) to A.N., and Grants-in-Aid for Scientific Research (C; No. 16K10652) to H.K. This study was partially supported by Grants-in-Aid for Scientific Research (B; No. JP16H03179) to H.C., the Center of Innovation (COI) Program from Japan Science and Technology Agency (JST) to K.K., and the Project for Cancer Research And Therapeutic Evolution (P-CREATE) (Project No. 16cm0106202h0001 ) from Japan Agency for Medical Research and Development (AMED) to K.K., H.C.
Publisher Copyright:
© 2018 The Authors
PY - 2018/9/28
Y1 - 2018/9/28
N2 - Peripheral artery disease (PAD) is one of the most spreading diseases all over the world. The treatment strategies are limited to surgical or endovascular procedures for final stage chronic PAD or acute limb ischemia, and no pharmacological approaches have been achieved to prevent the worsening of chronic PAD or to regenerate the tissues of acute limb ischemia. Therefore, the improvement of therapeutic strategy is strongly demanded in clinics. Here, we adopted an acute hindlimb ischemia model in rats, which provides concomitant inflammatory response, to evaluate the application of drug delivery system against PAD. Through comparative experiments by using different-sized nanomedicine analogues, polyion complex (PIC) micelles with 30 nm diameter and PIC vesicles with 100- and 200-nm diameter (PICs-30, −100, −200 respectively), we found the size-dependent accumulation and retention in the collateral arteries. In contrast to PICs-30 and -200, histological analysis showed that PICs-100 were around the arterioles and co-localized with macrophages, which indicates that the PICs-100 can achieve moderate interaction with phagocytes. Our data suggests that controlling the size of nanomedicines has promise for developing novel angiogenic treatments toward the effective management of collateral arteries.
AB - Peripheral artery disease (PAD) is one of the most spreading diseases all over the world. The treatment strategies are limited to surgical or endovascular procedures for final stage chronic PAD or acute limb ischemia, and no pharmacological approaches have been achieved to prevent the worsening of chronic PAD or to regenerate the tissues of acute limb ischemia. Therefore, the improvement of therapeutic strategy is strongly demanded in clinics. Here, we adopted an acute hindlimb ischemia model in rats, which provides concomitant inflammatory response, to evaluate the application of drug delivery system against PAD. Through comparative experiments by using different-sized nanomedicine analogues, polyion complex (PIC) micelles with 30 nm diameter and PIC vesicles with 100- and 200-nm diameter (PICs-30, −100, −200 respectively), we found the size-dependent accumulation and retention in the collateral arteries. In contrast to PICs-30 and -200, histological analysis showed that PICs-100 were around the arterioles and co-localized with macrophages, which indicates that the PICs-100 can achieve moderate interaction with phagocytes. Our data suggests that controlling the size of nanomedicines has promise for developing novel angiogenic treatments toward the effective management of collateral arteries.
UR - http://www.scopus.com/inward/record.url?scp=85051258230&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051258230&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2018.07.049
DO - 10.1016/j.jconrel.2018.07.049
M3 - Article
C2 - 30076876
AN - SCOPUS:85051258230
SN - 0168-3659
VL - 286
SP - 394
EP - 401
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -